Know Cancer

forgot password

Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial

Phase 2
18 Years
70 Years
Open (Enrolling)
Advanced Esophageal Squamous Carcinoma

Thank you

Trial Information

Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial

Inclusion Criteria:

- Having signed informed consent

- Age 18 to 70 years old

- Histologically confirmed esophageal squamous carcinoma, no prior palliative
chemotherapy; recurrence from last adjuvant chemotherapy or adjuvant radiotherapy
should be longer than 6 months; no prior treatment of irinotecan as adjuvant
chemotherapy, total dose of cisplatin is less than 300mg/m2 if used in adjuvant

- Unresectable recurrent or metastatic disease

- Measurable disease according to the RECIST criteria(diameter of the lesion should be
more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image
should be less than 15 days before enrollment)

- Karnofsky performance status ≥70

- Life expectancy of ≥3 month

- No prior radiotherapy except radiotherapy at non-target lesion of the study more than
4 weeks

- ALT and AST<2.5 times ULN (≤5 times ULN in patients with liver metastases)(within 7
days before enrollment)

- Serum AKP < 2.5 times ULN (within 7 days before enrollment)

- Serum creatinine <1.0 times ULN (within 7 days before enrollment)

- Bilirubin level < 1.0 times ULN (within 7 days before enrollment)

- WBC>4,000/mm3, absolute neutrophil count ≥2000/mm3, platelet>100,000/mm3,
Hb>9g/dl(within 7 days before enrollment)

- No sever complication, such as active gastrointestinal bleeding, perforation,
jaundice, obstruction, non-cancerous fever>38℃;

- Good compliance

Exclusion Criteria:

- previous treatment of palliative chemotherapy or recurrence less than 6 months from
time of last adjuvant chemo-/radiotherapy

- Known hypersensitivity to irinotecan

- Only with Brain or bone metastasis

- Tumor with length≥10cm, liver metastasis covers more than 50% of liver,or lung
metastasis covers more than 25% of lung

- No measurable lesions, eg. pleural fluid and ascites

- Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry

- Heart failure or other sever organ dysfunction, eg. coronary artery disease,
myocardial infarction within the last 6 months or

- Pregnancy or lactation period

- Other previous malignancy within 5 year, except non-melanoma skin cancer

- Chronic diarrhea

- Mentally abnormal or disable cognition,including CNS metastasis

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

overall survival

Outcome Time Frame:

2 year

Safety Issue:



China: Food and Drug Administration

Study ID:




Start Date:

August 2009

Completion Date:

August 2012

Related Keywords:

  • Advanced Esophageal Squamous Carcinoma
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Neoplasms, Squamous Cell
  • Esophageal Diseases